Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Ambien wakes up the market

Executive Summary

The first generic versions of Sanofi-Aventis' market-leading sleep aid Ambien (zolpidem immediate-release) launched immediately following FDA's first approvals April 23. No manufacturer holds generic exclusivity, and fifteen ANDAs are approved as of April 27. Prasco markets an authorized generic under a distribution and supply agreement with Sanofi. According to data from Gold Standard's pricing database ProspectoRx, the wholesale acquisition costs of the 5 mg generics range from $0.07 (Sandoz) to $0.25 (Apotex), compared to $4.11 per tablet for branded Ambien as of Feb. 16. In the last few years - as the insomnia market has heated up - the Ambien price has nearly doubled. In September 2004, just before the approval of Sepracor's Lunesta, the WAC was $2.09 for a 5 mg Ambien tablet and $2.57 for a 10 mg tablet. As of October, WAC for Sanofi's line-extension Ambien CR was $3.08 per 6.25 mg or 12.5 mg tablet...

You may also be interested in...

Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review

As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.

Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients

Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.

Teva’s Austedo Fails In Tourette’s Syndrome

Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts